Thus, a strong β2AR-specific PAM may improve asthma control by endogenous epinephrine and thus reduce or obviate the need for long-term use of inhaled β2-agonists without increasing the risk for epinephrine-induced adverse effects via other adrenergic receptor subtypes. This evidence concerns the gene ADRB2 and asthma.